PILOT: Cancer Immunotherapy (BioBusiness.TV Original Series)

This pilot was produced with the financial support of Celldex Therapeutics, Inc. - Sponsorships do not convey editorial privilege. BioBusiness.TV is an independent media.


What is a cancer immunotherapy product? Are cancer vaccines preventive or therapeutic? Are we controlling or curing cancer? Will treatments be reimbursed? What is the economic rationale for cancer immunotherapy products? What are some of the promising products in the pipeline? Is immunotherapy now a reality in the treatment of cancer?

Future episodes will cover:
- Understanding How the Immune System Works in Cancer
- Clinical Considerations for Cancer Immunotherapy
- Product Development
- Wall Street Perspectives
- Company Spotlights

Corporate sponsorships are available upon request.

Interviews conducted, on October 21st, 2010, in New York City.

Featured in this pilot (alphabetically):
- David Berd, Cancer Treatment Centers of America
- Martin A. Mac Cheever, University of Washington
- Charles G. Drake, Johns Hopkins
- Charles Duncan, JMP Securities
- Michael Fanger, Dartmouth Medical School
- Hervé Wolf Fridman, European Hospital Georges Pompidou, Cordeliers Research Centre
- James Gulley, National Cancer Institute/National Institutes of Health
- Tibor Keler, Celldex Therapeutics, Inc.
- Michael Lotze, University of Pittsburgh Cancer Institute, Clinical and Translational Research Institute
- Mark Monane, Needham & Co.
- Charles Nicolette, Argos Therapeutics
- Jill O'Donnell-Tormey, Cancer Research Institute (CRI)
- Stelios Papadopoulos
- Michael Sadelain, Memorial Sloan-Kettering Cancer Center
- Joel Sendek, Lazard Capital Markets
- Howard Soule, Prostate Cancer Foundation
- David Urdal, Dendreon Corporation

A BioBusiness.TV Original Production

Produced by:
- Jean-Loup Romet-Lemonne
- Jonathan Teper

Associate Producers
- Maury Raycroft
- Heba Nowyhed

Director of Photography:
- Andres Von Scheele